1. Home
  2. NBB vs FULC Comparison

NBB vs FULC Comparison

Compare NBB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Taxable Municipal Income Fund of Beneficial Interest

NBB

Nuveen Taxable Municipal Income Fund of Beneficial Interest

HOLD

Current Price

$15.45

Market Cap

456.2M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.74

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBB
FULC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
456.2M
467.8M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
NBB
FULC
Price
$15.45
$3.74
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
48.5K
1.4M
Earning Date
01-01-0001
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.95
$2.83
52 Week High
$16.62
$15.74

Technical Indicators

Market Signals
Indicator
NBB
FULC
Relative Strength Index (RSI) 53.98 46.98
Support Level $15.03 $3.44
Resistance Level $15.93 $3.96
Average True Range (ATR) 0.18 0.15
MACD 0.04 0.02
Stochastic Oscillator 74.45 55.68

Price Performance

Historical Comparison
NBB
FULC

About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest

Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund has single operating segment.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: